Remove Compounding Remove Generic Medicine Remove Vaccines
article thumbnail

STAT+: Pharmalittle: We’re reading about Lilly strategy against compounders, Bristol’s antipsychotic, and more

STAT

Novartis chief executive Vas Narasimhan and Paul Hudson, his counterpart at Sanofi, say the European Commission should set a spending target for medicines and vaccines to “fairly reward innovation.”  pays nearly three times as much for branded and generic medicines as other comparable countries, according to U.S.

article thumbnail

Drug Repurposing: Unlocking access to rare solutions

Express Pharma

Streamlined regulatory pathways One of the biggest enablers of drug repurposing is the regulatory framework designed to expedite approvals for already-approved compounds. For repurposed drugs, early-stage trials such as Phase 1 or 2 might be sufficient, provided there is existing safety data on the compound,” Vyas explains.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

World Standards Day: Recognizing How Standards Enable a Strong Medicines Supply Chain

Quality Matters

With this extensive system in place, patients can trust that medicines with the same name will be consistent in quality no matter who manufactures it or where in the world it is made. Since manufacturers know the precise quality specifications, standards help make the approval process for generic medicines more efficient.

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

The race to produce a vaccine which could protect the world against COVID-19 brought the topic of diversity in clinical trials, or lack of it, into sharp focus. Vaccines approved for public use require comprehensive RCTs to establish their safety and efficacy. The pandemic brought imbalances into sharp focus.

Packaging 143